Ticker

Analyst Price Targets — BEST

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
December 1, 2025 1:46 pmKumaraguru RajaLoop Capital Markets$8.00$2.78StreetInsider Brookline Capital Markets Starts Opus Genetics (IRD) at Buy

Latest News for BEST

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.

GlobeNewsWire • Jul 9, 2026
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program

CDER meeting expected to take place in the summer of 2026 in parallel with CBER's Type B Statistical Methods Meeting New York, New York and Rockville, Maryland--(Newsfile Corp. - July 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has accepted a new Meeting Request from the U.S.…

Newsfile Corp • Jul 8, 2026
S&T BANK NAMED A FORBES AMERICA'S BEST-IN-STATE BANK FOR 2026

INDIANA, Pa., June 17, 2026 /PRNewswire/ -- S&T Bank, the wholly owned subsidiary of S&T Bancorp, Inc. (NASDAQ:  STBA ), has been named to the Forbes America's Best-In-State Banks 2026 list, recognizing the financial institutions most valued by customers within their respective states.

PRNewsWire • Jun 17, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for BEST.

No House trades found for BEST.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top